Critical Review: Defiance Daily Target 2X Long LMND ETF (NASDAQ:LMNX) and Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ)

Risk & Volatility

Defiance Daily Target 2X Long LMND ETF has a beta of 9.67, meaning that its share price is 867% more volatile than the S&P 500. Comparatively, Health Sciences Acquisitions Co. 2 has a beta of 0.09, meaning that its share price is 91% less volatile than the S&P 500.

Institutional & Insider Ownership

87.8% of Defiance Daily Target 2X Long LMND ETF shares are owned by institutional investors. Comparatively, 89.7% of Health Sciences Acquisitions Co. 2 shares are owned by institutional investors. 6.6% of Defiance Daily Target 2X Long LMND ETF shares are owned by insiders. Comparatively, 21.9% of Health Sciences Acquisitions Co. 2 shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Defiance Daily Target 2X Long LMND ETF and Health Sciences Acquisitions Co. 2″s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Defiance Daily Target 2X Long LMND ETF	$437.66 million	0.02	$15.17 million	$0.51	43.94
Health Sciences Acquisitions Co. 2	N/A	N/A	-$380,000.00	N/A	N/A

Defiance Daily Target 2X Long LMND ETF has higher revenue and earnings than Health Sciences Acquisitions Co. 2.

Profitability

This table compares Defiance Daily Target 2X Long LMND ETF and Health Sciences Acquisitions Co. 2’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Defiance Daily Target 2X Long LMND ETF	5.39%	4.66%	2.91%
Health Sciences Acquisitions Co. 2	N/A	N/A	-2.38%

Summary

Defiance Daily Target 2X Long LMND ETF beats Health Sciences Acquisitions Co. 2 on 6 of the 8 factors compared between the two stocks.

About Defiance Daily Target 2X Long LMND ETF

Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; MicroPlex, MagPlex, xTAG, SeroMAP, and calibration and control microspheres; xPONENT, a software suite to simplify laboratory workflow and enhance productivity; and TDAS, an analysis program designed for development and optimization of nucleic acid assays. The company also provides xTAG assays and products to identify the causative agent for respiratory and gastrointestinal infections, as well as IVD kits for cystic fibrosis genotyping and pharmacogenetic assays used to profile genetic mutations related to drug metabolism; ARIES system, a sample to answer real-time PCR platform; SYNCT data management software solutions; and ARIES cassettes that are self-contained assay consumables, such as ARIES HSV 1&2 Assay, ARIES Flu A/B & RSV Assay, ARIES Group B Streptococcus Assay, ARIES Group A Strep Assay, ARIES Bordetella Assay, ARIES Norovirus Assay, ARIES C. difficile Assay, ARIES MRSA Assay, and SARS-CoV-2 Assay. In addition, it offers VERIGENE system, a semi-automated, multiplex, molecular analysis system for the clinical diagnostics market; VERIGENE test cartridges; Amnis FlowSight imaging flow cytometers; Amnis ImageStream Mark II imaging flow cytometers; Amnis CellStream for cell and particle analysis; Guava easyCyte benchtop flow cytometers; Muse cell analyzers; and IDEAS, an image analysis software. Luminex Corporation was founded in 1995 and is based in Austin, Texas.

About Health Sciences Acquisitions Co. 2

Health Sciences Acquisitions Corporation 2 does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or related business combination with one or more businesses in the biopharma and medical technology sectors in North America or Europe. Health Sciences Acquisitions Corporation 2 was incorporated in 2020 and is based in New York, New York.